Mohammad H. Azhdari

Mr. Mohammad H. Azhdari

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
MAMohammad H. Azhdari
Mohammad H. Azhdari
NGNima Goodarzi
Nima Goodarzi
DODavid O’sullivan
David O’sullivan
SDSeamas C. Donnelly
Seamas C. Donnelly
Lung cancer is a significant health problem worldwide. Unfortunately, current therapeutic strategies lack a sufficient level of specificity and can harm adjacent healthy cells. Consequently, to address the clinical need, novel approaches to improve treatment efficiency with minimal side effects are required. Nanotechnology can substantially contribute to the generation of differentiated products and improve patient outcomes. Evidence from previous research suggests that nanotechnology-based drug delivery systems could provide a promising platform for the targeted delivery of traditional chemotherapeutic drugs and novel small molecule therapeutic agents to treat lung cancer cells more effectively. This has also been found to improve the therapeutic index and reduce the required drug dose. Nanodrug delivery systems also provide precise control over drug release, resulting in reduced toxic side effects, controlled biodistribution, and accelerated effects or responses. This review highlights the most advanced and novel nanotechnology-based strategies, including targeted nanodrug delivery systems, stimuli-responsive nanoparticles, and bio-nanocarriers, which have recently been employed in preclinical and clinical investigations to overcome the current challenges in lung cancer treatments.

Verified
Journal Article
Open access
PDF file
MAMohammad H. Azhdari
Mohammad H. Azhdari
NGNima Goodarzi
Nima Goodarzi
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
Ronan MacLoughlinRonan MacLoughlin
Ronan MacLoughlin
Respiratory diseases are the cause of millions of deaths annually around the world. Despite the recent growth of our understanding of underlying mechanisms contributing to the pathogenesis of lung diseases, most therapeutic approaches are still limited to symptomatic treatments and therapies that only delay disease progression. Several clinical and preclinical studies have suggested stem cell (SC) therapy as a promising approach for treating various lung diseases. However, challenges such as the potential tumorigenicity, the low survival rate of the SCs in the recipient body, and difficulties in cell culturing and storage have limited the applicability of SC therapy. SC-derived extracellular vesicles (SC-EVs), particularly SC-derived exosomes (SC-Exos), exhibit most therapeutic properties of stem cells without their potential drawbacks. Similar to SCs, SC-Exos exhibit immunomodulatory, anti-inflammatory, and antifibrotic properties with the potential to be employed in the treatment of various inflammatory and chronic respiratory diseases. Furthermore, recent studies have demonstrated that the microRNA (miRNA) content of SC-Exos may play a crucial role in the therapeutic potential of these exosomes. Several studies have investigated the administration of SC-Exos via the pulmonary route, and techniques for SCs and SC-Exos delivery to the lungs by intratracheal instillation or inhalation have been developed. Here, we review the literature discussing the therapeutic effects of SC-Exos against respiratory diseases and advances in the pulmonary route of delivery of these exosomes to the damaged tissues.

7 August 2021 in Reviews in Medical Virology
Verified
Journal Article
Open access
PDF file
MDMaryam Yousefi Dehbidi
Maryam Yousefi Dehbidi
NGNima Goodarzi
Nima Goodarzi
MAMohammad H. Azhdari
Mohammad H. Azhdari
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is causing an ongoing pandemic of coronavirus disease 2019 (Covid‐19). Effective therapies are required for the treatment of patients with severe stages of the disease. Mesenchymal stem cells (MSCs) have been evaluated in numerous clinical trials, but present challenges, such as carcinogenic risk and special storage conditions, coupled with insufficient data about their mechanism of action. The majority of unique properties of MSCs are related to their paracrine activity and especially to their exosomes. The impact of MSCs‐derived exosomes (MSC‐Es) on complications of Covid‐19 has been investigated in several studies. MSC‐Es may improve some complications of Covid‐19 such as cytokine storm, acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Additionally, these exosomes can be evaluated as an applicable nano‐size carrier for antiviral therapeutic agents. Herein, we consider several potential applications of MSCs and their derived exosomes in the treatment of Covid‐19.

1 January 2022 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
HHHessam Hosseinkazemi
Hessam Hosseinkazemi
SSSaeed Samani
Saeed Samani
AOAndrew O’Neill
Andrew O’Neill
MSMahdieh Soezi
Mahdieh Soezi
MMMohsen Moghoofei
Mohsen Moghoofei
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
Breast cancer is the most common cancer diagnosed in women, with an estimated 12% of women in the United States affected during their lifetime. Researchers have demonstrated that early detection, diagnosis, and treatment are pivotal to increasing survival. The advent of nanotechnology has yielded several novel advances and available modern methods within the clinic to detect and treat breast cancer. Inorganic nanoparticles are broadly utilized for cancer diagnosis and therapeutic purposes. Interestingly, these nanoparticles can also be attached to tumor‐specific ligands and used to deliver chemotherapeutic or hormonal agents with high levels of tumor selectivity. Iron oxide nanoparticles are one of the most commonly used nanomaterials, which have attracted much attention to detect and treat breast cancers, owing to their superparamagnetic characteristics. Computerized tomography and magnetic resonance imaging (MRI) utilizing iron‐based magnetic nanoparticles are promising approaches for the radiological detection of breast cancer. Here, we discuss the roles and recent applications of iron oxide nanoparticles in diagnosing and treating breast cancer.